ADC Therapeutics S.A.
ADCTHealthcare|Biotechnology|CH
$1.58
-0.06 (-3.66%)
Cash / Share
$1.41
Clinical Trials (34)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05991388 A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | B-cell Non Hodgkin Lymphoma | P2P3 | Recruiting | 210 | Open-label | Odronextamab, Loncastuximab tesirine, Rituximab, Ifosfamide, Carboplatin, Etoposide, Etoposide Phosphate, Dexamethasone, CAR T-cells (TBC) |
| NCT04384484 Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | P3 | Active | 440 | RCT, Open-label | Loncastuximab Tesirine, Rituximab, Gemcitabine, Oxaliplatin |
| NCT05600686 Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | P2 | Active | 24 | Open-label | Cyclophosphamide, Doxorubicin, Etoposide, Loncastuximab Tesirine, Prednisone, Rituximab, Vincristine |
| NCT04998669 Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | Follicular Lymphoma | P2 | Recruiting | 100 | Open-label | Loncastuximab tesirine, Rituximab |
| NCT05190705 Loncastuximab Tesirine in WM | Waldenstrom Macroglobulinemia | P2 | Active | 21 | Open-label | Loncastuximab Tesirine, Dexamethasone |
| NCT05296070 Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | Marginal Zone Lymphoma | P2 | Recruiting | 50 | Open-label | Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg |
| NCT06788964 Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) | Relapsed or Refractory Large B-cell Lymphoma | P2 | Recruiting | 29 | Open-label | Loncastuximab Tesirine, Rituximab |
| NCT06919939 Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma | Large B-cell Lymphoma, Relapse | P2 | Recruiting | 26 | Open-label | Epcoritamab, Loncastuximab Tesirine |
| NCT04970901 A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | P1 | Active | 154 | Open-label | Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab |
| NCT06607549 Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) | Central Nervous System Lymphoma | P1 | Recruiting | 12 | Open-label | Loncastuximab tesirine and rituximab (Lonca-R) |
| NCT05971251 Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P1 | Active | 24 | Open-label | Loncastuximab Tesirine and Acalabrutinib |
| NCT03589469 Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | P2 | Completed | 145 | Open-label | Loncastuximab tesirine |
| NCT04639024 ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | P2 | Terminated | 3 | Open-label | ADCT-301 |
| NCT05144009 A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | P2 | Terminated | 41 | Open-label | Loncastuximab Tesirine, Rituximab |
| NCT07573436 Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) | Post-transplant Lymphoproliferative Disorder | P1P2 | Not Yet Recruiting | 23 | Open-label | Loncastuximab tesirine, Rituximab or rituximab biosimilar |
| NCT04052997 Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | P2 | Completed | 117 | Open-label | Camidanlumab Tesirine |
| NCT04082936 A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Follicular Lymphoma | P1P2 | Terminated | 97 | RCT, Open-label | imvotamab |
| NCT03684694 Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | P1P2 | Terminated | 136 | Open-label | Loncastuximab Tesirine, Ibrutinib |
| NCT03698552 ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | P1P2 | Terminated | 37 | Open-label | ADCT-602 |
| NCT04699461 Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma | Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | P2 | Terminated | 6 | RCT, Open-label | Loncastuximab Tesirine, Idelalisib |
| NCT05389462 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 128 | Open-label | ADCT-601, Gemcitabine |
| NCT03621982 Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer | P1 | Terminated | 78 | Open-label | ADCT-301, Pembrolizumab |
| NCT02669017 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | Non-Hodgkin Lymphoma, Burkitt's Lymphoma | P1 | Completed | 183 | Open-label | ADCT-402 |
| NCT02669264 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) | Acute Lymphoblastic Leukemia | P1 | Terminated | 35 | Open-label | ADCT-402 |
| NCT02588092 Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | P1 | Terminated | 35 | Open-label | ADCT-301 |
| NCT03685344 Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | P1 | Terminated | 13 | Open-label | Loncastuximab Tesirine and Durvalumab |
| NCT04972981 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 30 | Open-label | ADCT-901 |
| NCT04974996 A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | Diffuse Large B-Cell Lymphoma | P1 | Withdrawn | — | Open-label | Loncastuximab tesirine, Prednisone, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine |
| NCT05660395 A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | P1 | Terminated | 5 | Open-label | Loncastuximab Tesirine |
| NCT03700294 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 18 | Open-label | ADCT-601 |
| NCT03125200 Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | Breast Cancer, Non Small Cell Lung Cancer | P1 | Terminated | 21 | Open-label | ADCT-502 |
| NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | Hodgkin Lymphoma, Non-Hodgkin Lymphoma | P1 | Completed | 133 | Open-label | Camidanlumab tesirine |
| NCT04705454 Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | NO_LONGER_AVAILABLE | — | — | Loncastuximab Tesirine | |
| NCT05160064 Long-term Registry of Patients Treated With Loncastuximab Tesirine | B-Cell Lymphomas | Withdrawn | — | — | — |